地高辛抗体滴定剂量治疗急性地高辛中毒的临床经验(ATOM-6)
这项前瞻性观察研究纳入23例急性地高辛中毒患者(25次就诊),中位摄入剂量13 mg,治疗前中位心率41次/分。地高辛抗体后心率最大变化中位19次/分,血钾中位下降0.3 mmol/L,无急性地高辛中毒相关死亡。提示小剂量滴定策略可大幅减少抗体用量并节省费用。
要点
- 急性地高辛中毒患者(中位摄入13 mg、心率41次/分)采用1–2瓶重复滴定地高辛抗体,中位总剂量仅4瓶(IQR 2–7.5)。
- 滴定组总用量为按摄入量预测剂量的25%、按血药浓度预测剂量的35%,显著减少抗体用量。
- 地高辛抗体后心率中位最大变化19次/分,血钾中位下降0.3 mmol/L,临床反应安全可接受。
- 任何剂量地高辛抗体后游离地高辛浓度降至几乎为零,但10例出现地高辛反弹>2.6 nmol/L(2 µg/L)。
- 研究期间无急性地高辛中毒相关死亡。
适用人群与场景
- 经两个毒物信息中心和三个毒理学单位识别的急性地高辛中毒患者,中位年龄56岁,女性56%。
- 中位摄入剂量13 mg(IQR 9.5–25),治疗前中位心率41次/分,初始中位地高辛浓度14.5 nmol/L(11.2 µg/L),中位血钾5 mmol/L。
- 88%患者有胃肠道症状,20%患者有急性肾损伤。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 基于床旁心脏毒性评估,采用重复低剂量滴定地高辛抗体(Digoxin-Fab),而非大剂量冲击。
- 4例接受初始冲击剂量5–20瓶地高辛抗体。
- 任何剂量地高辛抗体后游离地高辛浓度降至几乎为零。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 前瞻性观察研究,纳入23例患者共25次就诊,来自两个毒物信息中心和三个毒理学单位,2013年9月至2020年9月。
- 滴定组总用量为按摄入量预测剂量的25%、按血药浓度预测剂量的35%。
- 地高辛抗体后心率中位最大变化19次/分,血钾中位下降0.3 mmol/L。
- 无急性地高辛中毒相关死亡。
证据类型、等级与局限
- 前瞻性观察研究,样本量小(23例患者,25次就诊),非随机对照,无对照组,来自两个毒物信息中心和三个毒理学单位。
对床旁实践的改变
- 急性地高辛中毒可基于床旁心脏毒性评估采用小剂量滴定地高辛抗体(1–2瓶/次),而非大剂量冲击,以显著减少总用量和费用。
- 滴定策略下需注意地高辛反弹(10例反弹>2.6 nmol/L),但原文未提及具体监测方案。
- 研究样本量小且为观察性设计,结论需前瞻性验证;原文未明确适用与不适用人群。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: For acute digoxin poisoning, it has been recommended to give bolus doses of 10-20 vials or potentially larger than needed doses calculated from dose ingested or the measured concentration. However, a recent revision of internal Poisons Information Centre guidelines prompted a change of our recommendations, specifically instead of large boluses, to use titrating repeated low doses of digoxin antibodies(Digoxin-Fab) based on bedside assessment of cardiac toxicity.
METHODS: This is a prospective observational study of patients with acute digoxin poisoning identified through two Poisons Information Centres and three toxicology units. Patient demographics, signs and symptoms of digoxin toxicity, doses and response to Digoxin-Fab, free and bound serum digoxin concentrations. Outcomes were recorded and analysed.
RESULTS: From September 2013 to September 2020, 23 patients with 25 presentations (median age 56 years, females 56%) were recruited. Median dose ingested was 13 mg(IQR: 9.5-25). Median heart rate (HR) was 41 beats/min before treatment. Initial median digoxin and potassium concentrations were 14.5 nmol/L (IQR: 10.9-20) [11.2 µg/L(IQR: 8.4-15.4)] and 5 mmol/L (IQR: 4.5-5.4 mmol/L), respectively. Gastrointestinal symptoms and acute kidney injury were present in 22 patients (88%) and 5 patients (20%), respectively. Four patients received an initial bolus dose of Digoxin-Fab of 5-20 vials. Twenty-one patients received repeated titrated doses (1-2 vials) of Digoxin-Fab and the median total dose was 4 vials (IQR: 2-7.5). Median maximal change in HR post-Digoxin-Fab was 19 beats/min. The median potassium concentration decrease post-Digoxin-Fab was 0.3 mmol/L. Total dose used in the titration group was 25% and 35% of the predicted doses based on the amount of digoxin ingested or measured serum concentration, respectively. Twelve had free digoxin concentrations measured. Free digoxin concentrations dropped to almost zero after any dose of Digoxin-Fab. Ten patients had a rebound of digoxin >2.6 nmol/L (2 µg/L). There were no deaths from acute digoxin toxicity.
CONCLUSIONS: The new practice of using small, titrated doses of Digoxin-Fab led to a considerable reduction in total usage and major savings. The clinical response to titrated doses was safe and acceptable in acute digoxin poisoning.
参考来源
- Chan BS, Isbister GK, Chiew A, et al. Clinical experience with titrating doses of digoxin antibodies in acute digoxin poisoning. (ATOM-6). Clin Toxicol (Phila). 2021. PMID: 34424803. doi:10.1080/15563650.2021.1968422
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。